These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 37545520)
1. HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. Zhang QQ; Zhang WJ; Chang S Front Immunol; 2023; 14():1168848. PubMed ID: 37545520 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of HDAC6 activity in kidney diseases: a new perspective. Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy. Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445 [TBL] [Abstract][Full Text] [Related]
4. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury. Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506 [TBL] [Abstract][Full Text] [Related]
5. Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology. Barone S; Cassese E; Alfano AI; Brindisi M; Summa V J Med Chem; 2022 Feb; 65(4):3080-3097. PubMed ID: 35148101 [TBL] [Abstract][Full Text] [Related]
6. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Batchu SN; Brijmohan AS; Advani A Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743 [TBL] [Abstract][Full Text] [Related]
7. 2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury. Hao Y; Guo F; Huang Z; Feng Y; Xia Z; Liu J; Li L; Huang R; Lin L; Ma L; Fu P Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894849 [TBL] [Abstract][Full Text] [Related]
8. Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses. Ren J; Liao X; Vieson MD; Chen M; Scott R; Kazmierczak J; Luo XM; Reilly CM Clin Exp Immunol; 2018 Jan; 191(1):19-31. PubMed ID: 28876451 [TBL] [Abstract][Full Text] [Related]
9. Degradation of histone deacetylase 6 alleviates ROS-mediated apoptosis in renal ischemia-reperfusion injury. Xia K; Qiu T; Jian Y; Liu H; Chen H; Liu X; Chen Z; Wang L Biomed Pharmacother; 2023 Sep; 165():115128. PubMed ID: 37429230 [TBL] [Abstract][Full Text] [Related]
10. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90. Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730 [TBL] [Abstract][Full Text] [Related]
11. HDAC6 Inhibition Alleviates Ischemia- and Cisplatin-Induced Acute Kidney Injury by Promoting Autophagy. Shi L; Song Z; Li C; Deng F; Xia Y; Huang J; Wu X; Zhu J Cells; 2022 Dec; 11(24):. PubMed ID: 36552715 [TBL] [Abstract][Full Text] [Related]
12. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury. Shi Y; Xu L; Tang J; Fang L; Ma S; Ma X; Nie J; Pi X; Qiu A; Zhuang S; Liu N Am J Physiol Renal Physiol; 2017 Mar; 312(3):F502-F515. PubMed ID: 28052874 [TBL] [Abstract][Full Text] [Related]
14. Recent Development of Novel HDAC6 Isoform-selective Inhibitors. Zhao Y; Liang T; Hou X; Fang H Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627 [TBL] [Abstract][Full Text] [Related]
15. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM Front Immunol; 2019; 10():2512. PubMed ID: 31708928 [TBL] [Abstract][Full Text] [Related]
16. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502 [TBL] [Abstract][Full Text] [Related]
17. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J Front Immunol; 2020; 11():590072. PubMed ID: 33329575 [TBL] [Abstract][Full Text] [Related]
18. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons. Iaconelli J; Xuan L; Karmacharya R Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935091 [TBL] [Abstract][Full Text] [Related]
19. HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT. Rossaert E; Van Den Bosch L Brain Res; 2020 Apr; 1733():146692. PubMed ID: 32006555 [TBL] [Abstract][Full Text] [Related]
20. HDAC6 as a potential therapeutic target for peripheral nerve disorders. Prior R; Van Helleputte L; Klingl YE; Van Den Bosch L Expert Opin Ther Targets; 2018 Dec; 22(12):993-1007. PubMed ID: 30360671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]